Gelteq Limited
GELSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Gelteq Limited (GELS) is listed under Drug Manufacturers - Specialty & Generic. At a $6.5M market cap, Gelteq Limited ranks as a micro-cap company within healthcare. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Market Cap
$6.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.53
EPS (Fwd)
—
ROE
-42.9%
ROA
-17.6%
Cash
$9,349
Total Debt
$5.1M
Free CF
-$4.8M
52W Change
-68.7%
Annual Financials
Cash vs Debt
Where GELS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, GELS finished 29.33% below its 150-day moving average ($0.75) and 38.37% below its 200-day moving average ($0.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GELS overbought or oversold?
At the July 15, 2026 close, GELS's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Gelteq Limited carries $5.1M in total debt against $9K in cash reserves — debt is roughly 547.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$4.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $148K to $166K.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GELS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.